CAR-T Therapy for Autoimmune Disease in Germany: What's Actually Happening

What This Article Covers

A cancer treatment is being repurposed, in a handful of German university hospitals, to attempt something that sounded implausible a few years ago: putting severe, drug-refractory autoimmune disease into sustained, medication-free remission. CAR-T (chimeric antigen receptor T-cell) therapy, already approved for certain blood cancers, is now the subject of a genuinely data-backed academic research program centered on Erlangen, with newer trial sites opening in Magdeburg and elsewhere in Germany. This article lays out what has actually been published, how many patients have actually been treated, what the real safety profile looks like, and where the regulatory line currently sits — because this is one of the rare "cutting edge" stories in regenerative medicine where the excitement is matched by peer-reviewed evidence, not just press releases.

The Erlangen Program: Where the Real Data Comes From

The center of gravity for this field is Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and its university hospital, Uniklinikum Erlangen, under rheumatologist Georg Schett. Starting in March 2021, the Erlangen team began treating patients with severe systemic lupus erythematosus (SLE), systemic sclerosis, and myositis using CD19-targeted CAR-T cells — the same basic technology used against B-cell lymphomas — to wipe out the B cells thought to be driving the autoimmune attack.

The landmark result, published in the New England Journal of Medicine in 2024 (Müller et al.), covered 15 patients and reported that B cells eventually regenerated after treatment but came back "naive" — immunologically reset rather than carrying the old autoreactive memory. Patients were able to stop cortisone and other immunosuppressants, several for years, without relapse. By early 2025, FAU reported more than 45 patients with various autoimmune diseases had been treated at Erlangen since the program began, including more than 15 with lupus specifically, with ongoing funding support from the US-based Lupus Research Alliance. In June 2025, the same group published a Nature Medicine case report describing a patient with anti-synthetase syndrome who achieved sustained, symptom-free remission after sequential CD19 and BCMA-targeted CAR-T treatment — a sign the approach is being extended beyond first-generation targets. Erlangen's CASTLE study is actively enrolling further patients.

Beyond Erlangen: A Growing National Network

Germany's activity isn't confined to one city. In 2025, Magdeburg University Hospital (UMMD), working with Helios Fachklinik Vogelsang-Gommern and backed by European Regional Development Fund money through its ZELLTHEMA project, announced it had become one of the first additional study centers in the country for CAR-T in autoimmune disease, having already treated two patients with lupus and inflammatory myopathy and planning trials in systemic sclerosis, myasthenia gravis, and multiple sclerosis. That a second, geographically distinct university center is now running its own early-phase trials — rather than simply citing Erlangen's results — is a meaningful signal that this is becoming a genuine national research infrastructure, not a single lab's experiment.

What the Science Actually Shows — and Doesn't

The encouraging signal is real: deep, sustained B-cell depletion appears able to interrupt the autoimmune cycle in a way that conventional immunosuppression rarely achieves, and the "immune reset" framing researchers use is backed by actual mechanistic follow-up, not just outcome counts. That said, the honest caveats matter just as much:

• Sample sizes remain small. Even Erlangen's combined patient count, built up over more than four years, is well under 100, and most published case series involve well under 20 people.
• Follow-up, while now reaching several years for the earliest patients, is still short relative to how long a chronic autoimmune disease needs to be tracked to call remission durable.
• Diseases studied are heterogeneous (lupus, scleroderma, myositis, anti-synthetase syndrome), and what works for one may not generalize cleanly to another.
• Independent experts in the field have cautioned that data so far comes from very small numbers of patients with heterogeneous diseases and very short follow-up, and that long-term effects of profound B-cell depletion and lymphodepleting chemotherapy in non-cancer patients are still unknown.

Safety: A More Favorable Picture Than Oncology CAR-T, With Real Caveats

CAR-T in cancer carries well-documented risks of cytokine release syndrome (CRS) and neurotoxicity, and regulators including Germany's Paul-Ehrlich-Institut have tracked rare secondary T-cell lymphoma case reports tied to approved CAR-T cancer products. In autoimmune disease, researchers in the field have noted that toxicity appears more limited, largely because the "antigen burden" from autoreactive B cells is far lower than in an advanced lymphoma or leukemia. But this is a comparative, not an absolute, safety claim: these remain small, academic, investigator-initiated trials, not an approved standard of care, and the longer-term risks of a near-complete immune reset in otherwise younger, non-cancer patients are genuinely unresolved.

Regulatory Reality: Investigational Only

No CAR-T product is approved by German or EU regulators (or the FDA) for any autoimmune indication. What's happening in Erlangen and Magdeburg is academic clinical trial research, using CAR-T constructs related to products already licensed for cancer but administered under research protocols, not commercial authorization. In the US, biotech company Kyverna Therapeutics' KYV-101 received FDA Fast Track designation for refractory lupus nephritis, underscoring that regulators globally are taking the approach seriously enough to accelerate review pathways — but "fast-tracked for study" is not "approved for patients." Anyone encountering marketing claims about CAR-T "curing" lupus or other autoimmune disease outside a registered clinical trial should treat that as a red flag; the legitimate version of this story is happening inside university hospital trial protocols, not direct-to-consumer clinics.

Where It's Headed

The trajectory is genuinely promising: a second German trial site opening, a widening list of target diseases, sequential multi-target CAR-T strategies showing early success, and sustained international funding interest all point to a field that is maturing rather than stalling. Larger, randomized, multi-center trials — and the follow-up to match — are the logical next step, and Germany's academic centers appear positioned to lead that work given their head start.

Bottom Line

Germany, specifically the Erlangen program and its newer counterpart in Magdeburg, currently has the most substantive, peer-reviewed clinical evidence base anywhere for CAR-T therapy in autoimmune disease. The results published so far — sustained, medication-free remission in a meaningful fraction of treated patients with severe lupus, scleroderma, and myositis — are a legitimate and exciting scientific advance, grounded in NEJM and Nature Medicine publications rather than hype. But the patient numbers remain small, follow-up is still relatively short, no regulator has approved the approach for autoimmune use, and this is academic trial medicine, not an available treatment — a distinction anyone researching this topic should keep firmly in view.